In the current state of knowledge, GLP-1 agonists remain contra-indicated in patients with a personal or family history of MTC or multiple endocrine neoplasia type-2 (Anonymous, 2010; Victoza (Liraglutide) Injection, 2012). Here, GLP1R is linked to medullary thyroid gland carcinoma.